Depressive symptoms · treatment‐resistant depression in adults
Switching to mianserin (60 mg/d) showed no clear difference in depressive symptoms (HAM‐D) Scale from: 0 to 54 (worse) compared with continuing on current antidepressant (fluoxetine 20 mg/d) (low certainty).
1 finding from 1 review
Adverse effects during antidepressant treatment period (0‐12 weeks) · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes adverse effects during antidepressant treatment period (0‐12 weeks) compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
Improvement in depression at 6‐12 weeks: HAM‐D score (continuous) · adults living with HIV and depression
1 finding from 1 review
Improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
Improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
Change in depressive symptoms · depression in adults
1 finding from 1 review
> 50% reduction in depressive symptoms · depression in adults
S‐adenosyl methionine as monotherapy showed no clear difference in proportions of participants responding to treatment ≥ 50% reduction… compared with SSRI antidepressant agent (low certainty).
1 finding from 1 review
Depression remission · depression in adults
S‐adenosyl methionine as monotherapy showed no clear difference in proportions of participants achieving remission depression rating… compared with SSRI antidepressant agent (low certainty).
1 finding from 1 review
Change in depressive symptoms · depression in adults
1 finding from 1 review
> 50% reduction in depressive symptoms · depression in adults
It is very uncertain whether S‐adenosyl methionine as monotherapy changes proportions of participants responding to treatment ≥ 50% reduction… compared with tricyclic antidepressant agent (very low certainty).
1 finding from 1 review
Depression remission · depression in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depressive symptoms · treatment of disordered and problem gambling
1 finding from 1 review
Depressive symptoms · treatment of disordered and problem gambling
1 finding from 1 review
Depressive symptoms · treatment of disordered and problem gambling
1 finding from 1 review
Depression (post‐treatment score on self report and clinician‐rated scales) Different self report and clinician‐rated scales (HDRS, BDI) · somatoform disorders in adults
1 finding from 1 review
Depression (post‐treatment score on self report and clinician‐rated scales) Different self report and clinician‐rated scales (HDRS, BDI) · somatoform disorders in adults
1 finding from 1 review
Depressive symptoms · somatoform disorders in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endpoint score (HDRS or MADRS) · somatoform disorders in adults
1 finding from 1 review
Leaving the study early · adults with psychotic depression
It is very uncertain whether antidepressant changes overall dropouts compared with placebo (very low certainty).
1 finding from 1 review
Leaving the study early · adults with psychotic depression
It is very uncertain whether antidepressant changes overall dropouts compared with antipsychotic (very low certainty).
1 finding from 1 review